Medicine shortages: 700 products at risk in Switzerland (cross-border guide)
Drugshortage.ch reports 67 medicines in critical shortage involving 42 active ingredients. The National Council supports the counterproposal.
Context
In brief
- More than 700 medicines are in short supply in Switzerland.
- 67 medicines are in critical or highly critical shortage.
- The analysis covers 42 distinct active ingredients.
- The process moves from the National Council to the Council of States.
Key facts
- Platform → drugshortage.ch
- Operator → Enea Martinelli, hospital pharmacist
- Initiative → «Yes to the Security of Medical Care»
- Affected medicines → more than 700
- Critical medicines → 67
- Distinct active ingredients → 42
- Next step → Council of States
More than 700 medicines are currently affected by supply shortages in Switzerland, according to drugshortage.ch, the platform managed by Enea Martinelli, a hospital pharmacist. Martinelli is also behind the popular initiative «Yes to the Security of Medical Care», which calls on the federal government to do more to ensure the availability of medicines. Supported by a broad coalition from the healthcare sector, the proposal was discussed this week in the National Council.
A broader database
Drugshortage.ch tracks shortages of individual packages. Much of the information comes from pharmaceutical companies and a wholesaler that supplies healthcare providers. Martinelli created the platform because he considered federal monitoring too narrow: the authorities collect data on shortages and interruptions, but mainly for medicines considered essential. His database therefore expands the scope monitored.
The platform’s analysis identifies 67 medicines, with 42 distinct active ingredients, classified as being in critical or highly critical shortage. Ten active ingredients are used in cancer treatments; five against bacterial or other types of infections; five for eye diseases and five for blood disorders. Others concern neurology, pain relief, heart disease, addictions and psychiatry, as well as endocrinology, obstetrics, anaesthesia and supportive care.
The parliamentary process
The political response is taking shape in Parliament. The National Council recommends that voters reject the initiative, but supports the Federal Council’s direct counter-proposal. Five of the six parliamentary groups acknowledge that the issue being addressed is real; the majority nevertheless prefers the government’s solution, considering it more targeted. The Swiss People's Party opposes both measures. The two measures now move to the Council of States. For a separate in-depth look at everyday health topics, see cassa malati.
Operational details
Medicine shortages are not a phenomenon unique to Switzerland. The source links them to the concentration of supply chains in developed countries: many active ingredients and finished medicines are produced by a handful of manufacturers. For those who live or work in Switzerland, the consequence to consider is the spread of risk: a problem at a single facility can affect supplies in several countries.
Where risk is concentrated
| Factor | Implication described by the source |
|---|---|
| Few manufacturers | Non-compliant quality or a production delay can reduce supplies in several countries. |
| Raw materials | A shortage of them can interrupt the availability of the finished product. |
| Transport | A logistical disruption can spread beyond the country where it occurs. |
| Demand | A sudden increase at a single facility can affect international supplies. |
| Swiss market | Its relatively small size may make it less attractive to maintain multiple suppliers or prioritize deliveries when stocks are scarce. |
| International production | Dependence on foreign countries exposes the Swiss market to problems that arise in the international supply chain. |
| Mandatory reserves | Some medicines on the list are already supplied from reserves; the state thus offsets weaknesses in the commercial supply chain. |
This structure changes how a shortage should be understood. The problem may originate at a single facility and affect several countries; the source lists various causes, from quality failures to a sudden increase in demand. The report therefore does not describe a single industrial dynamic, but rather a vulnerability that can change depending on which point in the supply chain is affected.
The categories identified by the source as most exposed are older generic medicines, antibiotics, injectable oncology drugs and opioids. They often have few suppliers or require complex production processes. The Swiss market adds a specific characteristic: its size may reduce manufacturers' interest in maintaining multiple supply channels or prioritizing deliveries when stocks are limited. To complement this perspective with a general overview of everyday expenses, consult costo della vita in Svizzera.
Useful tools to protect your net income
To reduce FX leakage, compare CHF-EUR exchange options and banks for cross-border workers.
Key points
To follow the dossier without confusing the different measures, the reader can use a simple sequence, based on the data reported by the platform and the parliamentary process.
Five reading steps
1. Start with the platform. The entry point is drugshortage.ch, which records shortages of individual packages. The entry consulted therefore concerns a medicine format, not automatically the set of active ingredients.
2. Identify the source of the data. The information comes largely from pharmaceutical companies and a wholesaler that supplies healthcare providers. This clarifies where a substantial part of the monitoring originates.
3. Read the indicated severity. The analysis distinguishes shortages classified as critical or very critical. This label should be kept separate from simple presence on the list, because the source uses different levels to describe severity.
4. Compare the scopes. Federal monitoring mainly concerns medicines considered essential, while Martinelli’s database broadens the scope. The two surveys therefore do not observe exactly the same set of products.
5. Follow the political process. The National Council recommended rejecting the initiative and supported the Federal Council’s direct counterproposal. The two measures now proceed to the Council of States, which represents the next step indicated by the source.
This sequence separates the package format, the severity of the shortage, the breadth of the monitoring and the institutional response. It makes it possible to read the dossier based on what is documented, without confusing the availability of a single package with the broader picture of the supply chain or with the outcome of the parliamentary debate. To learn more about the health topic in everyday life, consult cassa malati.
Evaluating a Ticino job offer? Simulate your net payslip: enter gross salary, marital status and municipality for a detailed breakdown.
Source: lenews.ch
Frequently Asked Questions
- How many medicines are currently in shortage in Switzerland?
- According to the drugshortage.ch platform, managed by hospital pharmacist Enea Martinelli, over 700 medicines are affected by supply shortages. Of these, 67 are classified as critically or very critically deficient, involving 42 distinct active substances. The database follows the individual packages, expanding the perimeter with respect to federal monitoring that focuses mainly on essential drugs.
- Which drug categories are most affected by the shortages?
- The source indicates that the most exposed categories are older generic medicines, antibiotics, injectable oncology drugs, and opioids. These products often have few suppliers or require complex production processes. In addition, the relatively small size of the Swiss market may make it less attractive for manufacturers to maintain multiple supply channels or prioritize deliveries when stocks are low.
- What is the status of the parliamentary process on the 'Yes to the Security of Medical Care' initiative?
- The National Council recommended voters to reject the popular initiative, instead supporting the direct counter-proposal of the Federal Council. Five of the six parliamentary groups recognise the reality of the problem but prefer the government's solution. The Swiss People's Party opposes both measures. The two measures now go to the Council of States for the next stage of discussion.